Amy Hedison Joins Exact Sciences as Director of Investor Relations.Business Editors and Health/Medical Writers MAYNARD, Mass.--(BW HealthWire)--Feb. 23, 2001 EXACT Sciences Corporation (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on : EXAS) today announced that Amy Seltzer Hedison has joined EXACT as Director of Investor Relations Investor relations The process by which the corporation communicates with its investors. . Prior to joining Exact, Ms. Hedison was Director of Investor Relations and Director of Marketing at Gomez, Inc., the Internet quality measurement firm. Prior to Gomez, Ms. Hedison spent six years at Biogen, Inc., a Cambridge, MA-based biopharmaceutical company, where she held several positions, including Director of Investor Relations. She was also a senior member of the marketing team that launched Biogen's first product, AVONEX(TM). "We are very pleased to have Amy as the newest member of the EXACT management team," said Don Hardison, President. "Her knowledge of investor relations and communications experience at several prestigious companies will be a significant asset to EXACT as we work towards presenting our genomics-based technologies to the world." Ms. Hedison holds a Master of Business Administration degree from the Tuck School of Business The Amos Tuck School of Business Administration is the business school of Dartmouth College in Hanover, New Hampshire. Founded in 1900, Tuck is the oldest graduate school of business in the world. at Dartmouth College Dartmouth College, at Hanover, N.H.; coeducational; chartered 1769, opened 1770, the ninth colonial college (see Wheelock, Eleazar). Originally a men's college, Dartmouth began admitting women in 1972. and a Bachelor of Arts degree from Princeton University. EXACT Sciences Corporation is an applied genomics applied genomics Molecular genetics Molecular medicine The use of genetic information to diagnose, prognosticate and manage disease, based on the techniques of PCR, real time-PCR, DNA sequencing, and gene rearrangement studies for leukemia and lymphoma. company that has developed proprietary technologies for the early detection of several types of cancers. EXACT has selected colorectal cancer colorectal cancer Malignant tumour of the large intestine (colon) or rectum. Risk factors include age (after age 50), family history of colorectal cancer, chronic inflammatory bowel diseases, benign polyps, physical inactivity, and a diet high in fat. as the first application of its technologies. Colorectal cancer is the most deadly cancer among non-smokers, and is curable cur·a·ble adj. Capable of being cured or healed. if detected early. Despite the availability of colorectal cancer screening and diagnostic tests for more than 20 years, the rate of early detection of colorectal cancer remains low. EXACT believes its technologies will enable early detection of colorectal cancer so that more people can be effectively treated. Founded in 1995, EXACT is based in Maynard, Mass. Detailed information on EXACT Sciences Corporation can be found on the World Wide Web at www.exactsciences.com. This press release may contain forward-looking statements that reflect management's current views of future events and operations. These forward-looking statements are based on assumptions, external factors and other risks that are detailed in the prospectus relating to this offering. Actual results could differ materially from these forward-looking statements. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion